Complete Filing Data
Cyclerion Therapeutics, Inc. reported Stockholders Equity of $9.09 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Cyclerion Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income * | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M | -$77.8M | -$123.0M | -$115.3M |
| Revenue * | $2.1M | $2.0M | $0.00 | $297.0K | $3.9M | $2.3M | $4.5M | |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $0.00 | -$6.0K | $8.0K | $3.0K | $4.0K | -$7.0K | -$20.0K | |
| Operating Expenses | $7.0M | $5.6M | $13.0M | $18.8M | $59.1M | $83.6M | $129.5M | $115.3M |
| Research And Development Expense | $959.0K | $286.0K | $1.5M | $6.0M | $37.6M | $56.4M | $95.1M | $87.7M |
| Operating Income Loss | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M | -$81.3M | -$125.0M | -$115.3M |
| General And Administrative Expense | $6.1M | $5.3M | $8.1M | $12.9M | $20.6M | $28.8M | $34.4M | $27.5M |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M | -$77.8M | -$123.0M | -$115.3M |
| Nonoperating Income Expense | $1.4M | $571.0K | $358.0K | $294.0K | -$16.0K | $588.0K | ||
| Accrued Research And Development Current | $198.0K | $52.0K | $90.0K | $2.3M | $6.4M | $1.4M | $2.2M | $5.3M |
| Revenue From Development Agreement | $0.00 | $297.0K | $320.0K | $0.00 | ||||
| Revenue From Grant | $1.3M | $622.0K | $0.00 | |||||
| Other Nonoperating Income | $128.0K | $208.0K | $358.0K | |||||
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | $0.00 | $3.14 | -$11.89 | |||||
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | $0.00 | $3.14 | -$11.89 | |||||
| Income Loss From Discontinued Operations Net Of Tax | $0.00 | $7.3M | -$25.8M | |||||
| Income Loss From Continuing Operations Per Diluted Share | -$1.21 | -$5.39 | -$8.40 | |||||
| Income Loss From Continuing Operations Per Basic Share | -$1.21 | -$5.39 | -$8.40 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$976.0K | -$324.0K | -$1.4M | -$723.0K | -$1.3M | -$1.5M | $7.6M | -$4.2M | -$7.0M | -$10.5M | -$13.4M | -$13.0M | -$11.3M | -$16.2M | -$7.0M | -$18.8M | -$19.5M | -$20.2M | -$27.3M | -$32.3M | -$37.4M | -$29.3M | -$29.8M | -$25.3M |
| Revenue * | $875.0K | $93.0K | $81.0K | $194.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $306.0K | $711.0K | $348.0K | $3.0M | $62.0K | $400.0K | $749.0K | $1.0M | $1.4M | $1.6M | ||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $0.00 | $0.00 | $0.00 | $0.00 | -$2.0K | -$4.0K | -$2.0K | $3.0K | $1.0K | -$3.0K | -$1.0K | -$1.0K | $0.00 | $1.0K | $391.0K | $3.0K | -$12.0K | $2.0K | $5.0K | -$4.0K | ||||
| Operating Expenses | $1.9M | $1.8M | $1.5M | $1.3M | $1.4M | $1.6M | $6.0M | $1.9M | $3.3M | $4.5M | $13.7M | $13.7M | $11.6M | $19.2M | $13.5M | $22.2M | $20.4M | $21.6M | $29.4M | $34.7M | $37.4M | $29.3M | $29.8M | $25.3M |
| Research And Development Expense | $348.0K | $56.0K | $36.0K | $81.0K | $105.0K | $44.0K | $580.0K | $339.0K | $572.0K | $1.4M | $10.2M | $9.7M | $7.0M | $12.1M | $8.1M | $13.7M | $13.8M | $16.8M | $22.3M | $25.8M | $26.4M | $21.5M | $22.3M | $21.5M |
| Operating Income Loss | -$1.0M | -$1.7M | -$1.5M | -$1.1M | -$1.4M | -$1.6M | -$6.0M | -$1.9M | -$3.3M | -$4.5M | -$13.4M | -$13.0M | -$11.3M | -$16.2M | -$13.4M | -$21.8M | -$19.7M | -$20.6M | -$28.0M | -$33.1M | -$37.4M | -$29.3M | -$29.8M | -$25.3M |
| General And Administrative Expense | $1.5M | $1.7M | $1.5M | $1.2M | $1.3M | $1.6M | $2.1M | $1.5M | $2.7M | $3.1M | $3.5M | $4.0M | $4.6M | $6.2M | $5.4M | $8.0M | $6.6M | $6.9M | $7.1M | $8.9M | $11.0M | $7.8M | $7.5M | $3.8M |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$976.0K | -$324.0K | -$1.4M | -$723.0K | -$1.3M | -$1.5M | $7.6M | -$4.2M | -$7.0M | -$10.5M | -$13.4M | -$13.0M | -$11.3M | -$16.2M | -$13.4M | -$18.8M | -$19.5M | -$20.2M | -$27.3M | -$32.3M | -$37.4M | -$29.3M | -$29.8M | |
| Nonoperating Income Expense | $30.0K | $1.3M | $28.0K | $405.0K | $62.0K | $76.0K | $107.0K | $62.0K | $88.0K | $111.0K | $45.0K | $6.0K | -$5.0K | -$6.0K | -$4.0K | $93.0K | $138.0K | $361.0K | ||||||
| Accrued Research And Development Current | $46.0K | $72.0K | $50.0K | $72.0K | $97.0K | $90.0K | $362.0K | $620.0K | $1.6M | $4.3M | $4.8M | $4.5M | $3.4M | $2.2M | $1.6M | $2.2M | $1.6M | $2.7M | $3.5M | $5.3M | $6.2M | |||
| Revenue From Development Agreement | $0.00 | $0.00 | $0.00 | $0.00 | $72.0K | $225.0K | $77.0K | $0.00 | $62.0K | $0.00 | ||||||||||||||
| Revenue From Grant | $0.00 | $0.00 | $0.00 | $234.0K | $486.0K | $271.0K | $0.00 | $0.00 | ||||||||||||||||
| Other Nonoperating Income | $30.0K | $31.0K | $28.0K | $42.0K | $62.0K | $76.0K | $107.0K | |||||||||||||||||
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | $0.00 | $0.00 | $0.00 | $4.84 | -$1.04 | -$1.73 | -$2.80 | |||||||||||||||||
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | $0.00 | $0.00 | $0.00 | $5.53 | -$1.04 | -$1.73 | -$2.80 | |||||||||||||||||
| Income Loss From Discontinued Operations Net Of Tax | $0.00 | $0.00 | $0.00 | $13.5M | -$2.4M | -$3.8M | -$6.1M | |||||||||||||||||
| Income Loss From Continuing Operations Per Diluted Share | -$0.29 | -$0.53 | -$0.62 | -$2.12 | -$0.79 | -$1.46 | -$2.03 | |||||||||||||||||
| Income Loss From Continuing Operations Per Basic Share | -$0.29 | -$0.53 | -$0.62 | -$2.43 | -$0.79 | -$1.46 | -$2.03 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $9.1M | $8.9M | $11.3M | $10.5M | $48.2M | $59.5M | $97.7M | -$10.4M | -$8.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M | $58.2M | $102.6M | $0.00 | |
| Cash And Cash Equivalents At Carrying Value | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M | $54.4M | $94.9M | ||
| Other Assets Current | $11.0K | $16.0K | $11.0K | $537.0K | $468.0K | $3.2M | $2.9M | $12.0K | |
| Liabilities Current | $900.0K | $725.0K | $2.1M | $7.6M | $11.1M | $17.0M | $18.2M | $17.8M | |
| Liabilities And Stockholders Equity | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M | $115.4M | $186.5M | $7.4M | |
| Assets Current | $4.6M | $4.2M | $8.0M | $14.8M | $55.5M | $58.5M | $101.2M | $879.0K | |
| Assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M | $115.4M | $186.5M | $7.4M | |
| Accounts Payable Current | $508.0K | $390.0K | $1.2M | $3.0M | $1.8M | $1.1M | $3.2M | $2.8M | |
| Accrued Expenses And Other Liabilities Current | $194.0K | $283.0K | $798.0K | $2.4M | $2.9M | $7.3M | $9.3M | $9.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $8.0K | -$4.3M | -$5.8M | -$40.6M | -$4.3M | -$44.4M | $102.6M | ||
| Retained Earnings Accumulated Deficit | -$271.0M | -$267.5M | -$264.4M | -$259.2M | -$215.1M | -$163.4M | -$85.6M | ||
| Additional Paid In Capital Common Stock | $280.1M | $276.3M | $275.7M | $269.6M | $263.3M | $222.9M | $183.4M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $0.00 | -$12.0K | -$20.0K | -$23.0K | -$27.0K | -$20.0K | |||
| Other Assets Noncurrent | $0.00 | $2.0M | $2.4M | $2.8M | $540.0K | $25.0K | |||
| Common Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Operating Lease Right Of Use Asset | $0.00 | $1.2M | $1.4M | $43.4M | $68.1M | ||||
| Accounts Receivable Net Current | $1.0M | $556.0K | $0.00 | $96.0K | $100.0K | $0.00 | |||
| Property Plant And Equipment Net | $0.00 | $65.0K | $6.9M | $11.6M | $6.5M | ||||
| Commitments And Contingencies | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Gain Loss On Sale Of Property Plant Equipment | $0.00 | -$6.3M | $159.0K | -$751.0K | |||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Other Long Term Investments | $5.4M | $5.4M | $5.4M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $9.5M | $8.6M | $8.8M | $8.2M | $8.8M | $9.9M | $12.9M | $5.2M | $3.9M | $16.5M | $25.4M | $37.0M | $56.4M | $65.2M | $48.4M | $75.4M | $66.1M | $81.5M | $119.2M | $141.2M | -$7.8M | -$8.1M | -$8.6M | -$4.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $4.6M | $3.0M | $3.6M | $2.9M | $4.6M | $5.7M | $9.1M | $5.6M | $7.2M | $20.4M | $30.3M | $41.1M | $62.5M | $70.4M | $45.3M | $70.7M | $61.5M | $72.1M | $124.8M | $148.8M | $0.00 | $0.00 | $0.00 | ||
| Cash And Cash Equivalents At Carrying Value | $4.6M | $3.0M | $3.6M | $2.9M | $4.6M | $5.7M | $9.1M | $5.6M | $7.2M | $20.4M | $30.3M | $41.1M | $62.5M | $70.4M | $41.4M | $66.8M | $56.5M | $67.1M | $117.0M | $141.0M | |||||
| Other Assets Current | $11.0K | $27.0K | $21.0K | $11.0K | $11.0K | $10.0K | $30.0K | $428.0K | $503.0K | $488.0K | $482.0K | $477.0K | $459.0K | $1.8M | $1.8M | $1.7M | $89.0K | $136.0K | $68.0K | $28.0K | $12.0K | ||||
| Liabilities Current | $877.0K | $800.0K | $1.1M | $700.0K | $1.3M | $1.4M | $2.3M | $4.9M | $7.5M | $8.5M | $9.9M | $9.5M | $11.4M | $10.5M | $13.5M | $16.3M | $15.6M | $11.4M | $19.1M | $21.9M | $17.5M | ||||
| Liabilities And Stockholders Equity | $10.4M | $9.4M | $9.8M | $8.9M | $10.1M | $11.4M | $15.2M | $10.1M | $11.5M | $25.1M | $35.2M | $46.5M | $67.7M | $75.7M | $100.0M | $131.4M | $128.0M | $140.0M | $209.7M | $235.5M | $9.8M | ||||
| Assets Current | $5.1M | $4.0M | $4.5M | $3.5M | $4.7M | $6.0M | $9.9M | $7.1M | $8.3M | $21.7M | $31.7M | $42.8M | $63.7M | $73.0M | $44.4M | $70.1M | $59.6M | $70.1M | $120.7M | $144.7M | $939.0K | ||||
| Assets | $10.4M | $9.4M | $9.8M | $8.9M | $10.1M | $11.4M | $15.2M | $10.1M | $11.5M | $25.1M | $35.2M | $46.5M | $67.7M | $75.7M | $100.0M | $131.4M | $128.0M | $140.0M | $209.7M | $235.5M | $9.8M | ||||
| Accounts Payable Current | $480.0K | $462.0K | $483.0K | $304.0K | $651.0K | $741.0K | $814.0K | $1.9M | $3.9M | $1.6M | $2.8M | $2.5M | $1.2M | $1.4M | $1.1M | $1.4M | $2.2M | $1.5M | $4.8M | $6.9M | $5.7M | ||||
| Accrued Expenses And Other Liabilities Current | $351.0K | $266.0K | $534.0K | $324.0K | $534.0K | $610.0K | $1.2M | $2.5M | $2.0M | $2.6M | $2.3M | $2.4M | $3.2M | $3.4M | $3.9M | $5.6M | $5.1M | $4.6M | $7.3M | $7.0M | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $407.0K | -$1.9M | -$6.2M | -$12.8M | -$13.0M | -$30.5M | $0.00 | ||||||||||||||||||
| Retained Earnings Accumulated Deficit | -$270.2M | -$269.2M | -$268.9M | -$268.0M | -$267.3M | -$266.0M | -$262.7M | -$270.3M | -$266.1M | -$251.9M | -$241.4M | -$228.1M | -$204.3M | -$193.0M | -$176.8M | -$144.2M | -$125.4M | -$105.9M | -$59.6M | -$32.3M | |||||
| Additional Paid In Capital Common Stock | $279.8M | $277.8M | $277.7M | $276.2M | $276.1M | $275.9M | $275.6M | $275.5M | $270.1M | $268.5M | $266.8M | $265.1M | $260.7M | $258.3M | $225.3M | $219.6M | $191.5M | $187.4M | $178.8M | $173.4M | |||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $0.00 | $0.00 | -$16.0K | -$18.0K | -$16.0K | -$19.0K | -$28.0K | -$25.0K | -$24.0K | -$26.0K | -$26.0K | -$27.0K | -$27.0K | -$30.0K | -$18.0K | $1.0K | -$4.0K | ||||||||
| Other Assets Noncurrent | $0.00 | $1.9M | $2.0M | $2.1M | $2.2M | $2.3M | $2.5M | $2.6M | $2.7M | $2.9M | $1.4M | $1.1M | $19.0K | ||||||||||||
| Common Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||
| Operating Lease Right Of Use Asset | $0.00 | $1.1M | $1.2M | $1.3M | $1.3M | $1.4M | $1.4M | $42.4M | $44.4M | $51.3M | $52.3M | $69.2M | $70.3M | $71.3M | |||||||||||
| Accounts Receivable Net Current | $100.0K | $525.0K | $581.0K | $44.0K | $0.00 | $0.00 | $96.0K | $227.0K | $227.0K | $227.0K | $158.0K | ||||||||||||||
| Property Plant And Equipment Net | $0.00 | $0.00 | $17.0K | $112.0K | $153.0K | $65.0K | $10.2M | $10.8M | $11.6M | $12.1M | $12.8M | $8.8M | |||||||||||||
| Commitments And Contingencies | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||
| Gain Loss On Sale Of Property Plant Equipment | $0.00 | $0.00 | $12.0K | $41.0K | |||||||||||||||||||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||||||
| Other Long Term Investments | $5.4M | $5.4M | $5.4M | $5.4M | $5.4M | $5.4M | $5.4M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Share Based Compensation | $441.0K | $625.0K | $1.1M | $6.3M | $9.6M | $15.0M | $19.6M | $12.4M |
| Net Cash Provided By Used In Operating Activities | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M | -$72.5M | -$102.2M | -$97.5M |
| Increase Decrease In Prepaid Expense | -$37.0K | -$21.0K | -$363.0K | -$123.0K | $112.0K | $1.2M | $1.1M | -$384.0K |
| Increase Decrease In Accrued Research And Development | $146.0K | -$38.0K | -$2.2M | -$4.1M | $4.9M | -$776.0K | -$3.1M | $356.0K |
| Increase Decrease In Other Current Assets | -$5.0K | $5.0K | -$160.0K | $69.0K | -$1.2M | -$55.0K | $115.0K | $4.0K |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | -$89.0K | -$515.0K | -$1.6M | -$522.0K | -$4.3M | -$2.0M | -$1.6M | $2.0M |
| Increase Decrease In Accounts Payable Trade | $118.0K | -$445.0K | -$1.8M | $1.1M | $679.0K | -$1.3M | -$331.0K | $979.0K |
| Net Cash Provided By Used In Financing Activities | $3.3M | $0.00 | $5.0M | $29.0K | $30.8M | $28.1M | $211.6M | $100.9M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $0.00 | -$6.0K | $8.0K | $3.0K | $4.0K | -$7.0K | -$20.0K | |
| Increase Decrease In Other Noncurrent Assets | $0.00 | -$213.0K | -$366.0K | -$366.0K | -$888.0K | $515.0K | -$55.0K | |
| Net Cash Provided By Used In Investing Activities | $0.00 | $10.4M | $0.00 | $1.5M | $18.0K | -$6.7M | -$3.4M | |
| Increase Decrease In Operating Lease Assets | $0.00 | -$108.0K | -$184.0K | $59.0K | -$2.6M | -$3.1M | ||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 0.00 | 24.0K | 29.0K | 282.0K | 331.0K | 510.0K | ||
| Increase Decrease In Accounts Receivable | $444.0K | $556.0K | -$96.0K | -$4.0K | $100.0K | $0.00 | ||
| Increase Decrease In Accounts Receivable Related Parties | $0.00 | -$127.0K | $1.3M | $1.5M | ||||
| Payments To Acquire Property Plant And Equipment | $0.00 | $7.0K | $1.5M | $6.9M | $3.4M | |||
| Increase Decrease In Operating Lease Liabilities | $0.00 | -$1.0M | -$2.7M | $2.7M | ||||
| Increase Decrease In Accounts Payable Related Parties | $0.00 | -$286.0K | $205.0K | $81.0K | ||||
| Proceeds From Sale Of Property Plant And Equipment | $0.00 | $1.5M | $1.5M | $173.0K | ||||
| Proceeds From Issuance Of Common Stock | $1.4M | $0.00 | $5.0M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|
| Share Based Compensation | $114.0K | $181.0K | $426.0K | $1.8M | $2.3M | $4.0M | $4.0M | $2.5M |
| Net Cash Provided By Used In Operating Activities | -$968.0K | -$1.9M | -$6.2M | -$12.8M | -$14.5M | -$29.2M | -$34.3M | -$26.4M |
| Increase Decrease In Prepaid Expense | -$165.0K | -$134.0K | -$238.0K | $79.0K | $396.0K | -$98.0K | $60.0K | $19.0K |
| Increase Decrease In Accrued Research And Development | -$2.0K | $0.00 | -$670.0K | -$1.8M | $199.0K | $484.0K | $982.0K | -$2.2M |
| Increase Decrease In Other Current Assets | $5.0K | $0.00 | -$34.0K | $9.0K | $92.0K | $9.0K | -$8.0K | |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | $121.0K | -$188.0K | -$381.0K | -$470.0K | -$3.4M | -$4.7M | -$5.3M | |
| Increase Decrease In Accounts Payable Trade | $93.0K | -$456.0K | $955.0K | $691.0K | -$54.0K | -$1.0M | $2.9M | |
| Net Cash Provided By Used In Financing Activities | $1.4M | $0.00 | $0.00 | $27.0K | $1.0K | $36.1M | $26.6M | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $0.00 | -$4.0K | $1.0K | -$1.0K | $0.00 | $2.0K | $0.00 | |
| Increase Decrease In Other Noncurrent Assets | $0.00 | -$91.0K | -$91.0K | -$91.0K | $519.0K | -$6.0K | -$18.0K | |
| Net Cash Provided By Used In Investing Activities | $0.00 | $1.5M | -$1.4M | -$1.8M | -$162.0K | |||
| Increase Decrease In Operating Lease Assets | $0.00 | -$47.0K | -$46.0K | -$1.0M | $5.5M | |||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 0.00 | 27.0K | 1.0K | |||||
| Increase Decrease In Accounts Receivable | $25.0K | $0.00 | $0.00 | $127.0K | $0.00 | |||
| Increase Decrease In Accounts Receivable Related Parties | $0.00 | -$127.0K | -$448.0K | |||||
| Payments To Acquire Property Plant And Equipment | $1.4M | $1.8M | $162.0K | |||||
| Increase Decrease In Operating Lease Liabilities | $0.00 | -$774.0K | -$699.0K | |||||
| Increase Decrease In Accounts Payable Related Parties | $0.00 | -$286.0K | -$22.0K | |||||
| Proceeds From Sale Of Property Plant And Equipment | $0.00 | $1.5M | $49.0K | |||||
| Proceeds From Issuance Of Common Stock | $1.4M | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.11 | -$1.21 | -$2.25 | -$20.28 | -$1.32 | -$2.56 | -$4.49 | -$4.21 |
| Common Stock Shares Outstanding | 3.8M | 2.5M | 2.5M | 2.2M | 43.4M | 27.6M | 0.00 | |
| Common Stock Shares Issued | 3.9M | 2.7M | 2.6M | 2.2M | 43.4M | 27.6M | 0.00 | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Authorized | 400.0M | 400.0M | 400.0M | 20.0M | 400.0M | 400.0M | 400.0M | |
| Weighted Average Number Of Shares Outstanding Basic | 3.2M | 2.5M | 2.3M | 2.2M | 39.1M | |||
| Weighted Average Number Of Diluted Shares Outstanding | 3.2M | 2.5M | 2.3M | 2.2M | 39.1M | |||
| Earnings Per Share Basic | $-1.11 | $-1.21 | $-2.25 | $-20.28 | $-1.32 | |||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 39.1M | 30.4M | 27.4M | 27.4K | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Preferred Stock Shares Authorized | 100.0M | 100.0M | 100.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.30 | -$0.11 | -$0.56 | -$0.29 | -$0.53 | -$0.62 | $2.72 | -$1.83 | -$3.20 | -$4.83 | -$6.16 | -$0.30 | -$0.26 | -$0.45 | -$0.39 | -$0.59 | -$0.70 | -$0.73 | -$1.00 | -$1.18 | -$1.37 | -$1.07 | -$1.09 | |
| Common Stock Shares Outstanding | 3.7M | 3.1M | 3.1M | 2.5M | 2.5M | 2.5M | 2.4M | 2.4M | 43.5M | 43.5M | 43.5M | 43.4M | 43.3M | 43.3M | 34.1M | 34.0M | 34.0M | 27.9M | 27.8M | 27.5M | 27.4M | 0.00 | ||
| Common Stock Shares Issued | 3.8M | 3.2M | 3.2M | 2.7M | 2.7M | 2.7M | 2.4M | 2.4M | 43.5M | 43.5M | 43.5M | 43.4M | 43.3M | 43.3M | 34.1M | 34.0M | 34.0M | 27.9M | 27.8M | 27.5M | 27.4M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Authorized | 400.0M | 400.0M | 400.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | |||
| Weighted Average Number Of Shares Outstanding Basic | 3.2M | 3.1M | 2.6M | 2.5M | 2.5M | 2.5M | 2.4M | 2.3M | 2.2M | 2.2M | 2.2M | 43.4K | 43.3M | 35.7M | ||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 3.2M | 3.1M | 2.6M | 2.5M | 2.5M | 2.5M | 2.8M | 2.3M | 2.2M | 2.2M | 2.2M | 43.4K | 43.3M | 35.7M | ||||||||||
| Earnings Per Share Basic | $-0.30 | $-0.11 | $-0.56 | $-0.29 | $-0.53 | $-0.62 | $3.10 | $-1.83 | $-3.20 | $-4.83 | $-6.16 | $-0.30 | $-0.26 | $-0.45 | ||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 43.4M | 43.3M | 35.7M | 34.1M | 32.1M | 27.8M | 27.7M | 27.4M | 27.4M | 27.4K | 27.4K | 27.4K | ||||||||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||||
| Preferred Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 500.0K | 500.0K | 500.0K | 500.0K | 500.0K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $441.0K | $625.0K | $1.0M | $5.1M | $7.9M | $15.0M | $15.6M | |
| Prepaid Expense Current | $384.0K | $421.0K | $442.0K | $805.0K | $928.0K | $816.0K | $2.0M | $867.0K |
| Depreciation And Amortization | $0.00 | $65.0K | $472.0K | $2.3M | $2.7M | $1.5M | ||
| Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans | $24.0K | $29.0K | $282.0K | $331.0K | $510.0K | |||
| Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees | $25.0K | $1.2M | $1.7M | |||||
| Stock Issued During Period Value New Issues | $2.1M | $2.0M | $30.5M | $24.3M | $164.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $118.0K | $114.0K | $114.0K | $138.0K | $184.0K | $181.0K | $159.0K | $379.0K | $426.0K | $1.4M | $1.4M | $1.5M | $2.0M | $1.9M | $1.9M | $3.8M | $4.0M | $4.0M | $4.9M | $6.2M | $4.0M | $2.5M | ||
| Prepaid Expense Current | $386.0K | $462.0K | $256.0K | $621.0K | $116.0K | $308.0K | $726.0K | $1.0M | $567.0K | $536.0K | $647.0K | $1.0M | $562.0K | $766.0K | $1.2M | $1.2M | $2.3M | $1.9M | $2.2M | $1.8M | $927.0K | |||
| Depreciation And Amortization | $0.00 | $48.0K | $600.0K | $100.0K | $258.0K | $600.0K | $600.0K | $626.0K | $700.0K | $800.0K | $525.0K | $400.0K | $400.0K | $356.0K | ||||||||||
| Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans | $24.0K | $0.00 | $17.0K | $37.0K | $133.0K | $27.0K | $16.0K | $155.0K | $1.0K | $372.0K | ||||||||||||||
| Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees | $5.0K | $6.0K | $10.0K | $290.0K | $289.0K | $291.0K | $394.0K | $398.0K | $391.0K | |||||||||||||||
| Stock Issued During Period Value New Issues | $1.8M | $2.0M | $6.0K | $30.5M | $24.3M | $164.6M |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 7, 2026.